...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of asthma >Tiotropium added to low- to medium-dose inhaled corticosteroids (ICS) versus low- to medium-dose ICS alone for adults with mild to moderate uncontrolled persistent asthma: A systematic review and meta-analysis
【24h】

Tiotropium added to low- to medium-dose inhaled corticosteroids (ICS) versus low- to medium-dose ICS alone for adults with mild to moderate uncontrolled persistent asthma: A systematic review and meta-analysis

机译：将噻托溴酸加入低至中剂量吸入的皮质类固醇（ICS）与低至中剂量ICS单独用于轻度至中度不受控制的持久性哮喘的成人：系统审查和荟萃分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: To assess the efficacy and safety profile of tiotropium when added to low- to medium-dose inhaled corticosteroid (ICS) regimen versus low- to medium-dose ICS alone for adults with mild to moderate uncontrolled persistent asthma. Data Sources: The online databases Pubmed, Embase and the Cochrane Library were searched for relevant data published up to November 14, 2017; we also conducted a supplementary search using clinicaltrials.gov. Study Selections: Only randomized control trials were included in this review. Results: Four studies met our inclusion criteria for this review. In our review, two crossover studies were rated as "high risk" in the domain of "other bias" because a washout was not performed between each intervention. Lung function was significantly improved in the patient group receiving low- to medium-dose ICS with tiotropium. Results were consistent between each of three subgroups (tiotropium dry powder inhaler 18 mu g or Respimat Soft Mist inhaler 5 mu g, Respimat Soft Mist inhaler 2.5 mu g, and Respimat Soft Mist inhaler 1.25 mu g). Although no significant difference in Asthma Control Questionnaire (ACQ) score was found between the two treatment groups, substantial heterogeneity was observed. The incidence of serious adverse events between the two treatment groups was not statistically significant. Conclusions: Tiotropium as a once daily add-on to low- to medium-dose ICS may be efficacious and well-tolerated treatment in adults with moderate uncontrolled asthma. However, as only a few studies were identified, more studies of better design and long-term trial duration are required in the future.
机译：目的：评估噻噻um加入到低至中剂量吸入皮质类固醇（ICS）方案与低至中剂量IC的毒性和安全性曲线，单独用于含有轻度至中等不受控制持续哮喘的成人。数据源：搜索了在线数据库，Embase和Cochrane图书馆，达到2017年11月14日的相关数据;我们还使用ClinicalTrials.gov进行了补充搜索。学习选择：本次审查中只包含随机控制试验。结果：四项研究达到了本综述的纳入标准。在我们的评论中，两个交叉研究被评为“其他偏见”领域的“高风险”，因为在每种干预之间没有进行冲洗。用噻托尼亚接受低至中剂量IC的患者组显着改善肺功能。结果在三个亚组中的每一个（噻托溴酸干粉吸入器18μg或respimat软雾吸入器5 mu g，Respimat软雾吸入器2.5 mu g，并重新擦拭软雾吸入器1.25 mu g）。虽然在两个治疗组之间发现了哮喘对照问卷（ACQ）评分的显着差异，但观察到大量的异质性。两种治疗组之间的严重不良事件发生率并不统计学意义。结论：脱毒液作为低至中剂量IC的每日加入，可能是在具有中等不受控制的哮喘的成人中有效且耐受性的耐受性。然而，由于未发现一些研究，将来需要更多的研究更好的设计和长期试验期。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号